Published in AIDS on March 13, 2011
Elevated Cancer-Specific Mortality Among HIV-Infected Patients in the United States. J Clin Oncol (2015) 2.40
Moving forward in HIV-associated cancer. J Clin Oncol (2014) 2.14
Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era. J Natl Cancer Inst (2013) 1.96
Epidemiology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest (2013) 1.77
Outcome of HIV-associated lymphoma in a resource-limited setting of Jos, Nigeria. Infect Agent Cancer (2017) 1.39
Incidence and timing of cancer in HIV-infected individuals following initiation of combination antiretroviral therapy. Clin Infect Dis (2013) 1.31
Contribution of HIV infection to mortality among cancer patients in Uganda. AIDS (2013) 1.19
The latency-associated nuclear antigen, a multifunctional protein central to Kaposi's sarcoma-associated herpesvirus latency. Future Microbiol (2011) 1.13
Cancer-Related Causes of Death among HIV-Infected Patients in France in 2010: Evolution since 2000. PLoS One (2015) 1.01
HIV viremia and incidence of non-Hodgkin lymphoma in patients successfully treated with antiretroviral therapy. Clin Infect Dis (2014) 1.00
High cancer-related mortality in an urban, predominantly African-American, HIV-infected population. AIDS (2013) 0.99
Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study. BMC Infect Dis (2013) 0.98
Factors contributing to risk for cancer among HIV-infected individuals, and evidence that earlier combination antiretroviral therapy will alter this risk. Curr Opin HIV AIDS (2014) 0.93
Survival in HIV-infected patients after a cancer diagnosis in the cART Era: results of an italian multicenter study. PLoS One (2014) 0.92
Association of early HIV viremia with mortality after HIV-associated lymphoma. AIDS (2013) 0.92
Survival among HIV-infected and HIV-uninfected individuals with common non-AIDS-defining cancers. Cancer Epidemiol Biomarkers Prev (2015) 0.92
AIDS-Related Non-Hodgkin's Lymphoma in Sub-Saharan Africa: Current Status and Realities of Therapeutic Approach. Lymphoma (2012) 0.91
Factors associated with cancer incidence and with all-cause mortality after cancer diagnosis among human immunodeficiency virus-infected persons during the combination antiretroviral therapy era. Open Forum Infect Dis (2014) 0.90
HIV-1 Nef in macrophage-mediated disease pathogenesis. Int Rev Immunol (2012) 0.86
Epidemiology, Diagnosis, and Treatment of HIV-Associated Non-Hodgkin Lymphoma in Resource-Limited Settings. Adv Hematol (2012) 0.86
Site-specific association with host and viral chromatin by Kaposi's sarcoma-associated herpesvirus LANA and its reversal during lytic reactivation. J Virol (2014) 0.86
Clinical presentation, treatment, and outcomes among 65 patients with HIV-associated lymphoma treated at the University of North Carolina, 2000-2010. AIDS Res Hum Retroviruses (2011) 0.84
Factors associated with survival among patients with AIDS-related primary central nervous system lymphoma. AIDS (2014) 0.82
Relationship of immunologic response to antiretroviral therapy with non-AIDS defining cancer incidence. AIDS (2014) 0.81
Lymphoma immune reconstitution inflammatory syndrome in the center for AIDS research network of integrated clinical systems cohort. Clin Infect Dis (2014) 0.81
Ascertainment and verification of end-stage renal disease and end-stage liver disease in the north american AIDS cohort collaboration on research and design. AIDS Res Treat (2015) 0.80
Developing clinical strength-of-evidence approach to define HIV-associated malignancies for cancer registration in Kenya. PLoS One (2014) 0.79
The evolving scenario of non-AIDS-defining cancers: challenges and opportunities of care. Oncologist (2014) 0.77
Patterns of HIV viremia and viral suppression before diagnosis of non-AIDS-defining cancers in HIV-infected individuals. Infect Agent Cancer (2015) 0.77
The Spectrum of Malignancies among Adult HIV Cohort in Poland between 1995 and 2012: A Retrospective Analysis of 288 Cases. Contemp Oncol (Pozn) (2015) 0.77
Factors associated with time-to-treatment of prostate cancer in Florida. J Health Care Poor Underserved (2013) 0.77
Association of injection drug use with incidence of HIV-associated non-AIDS-related morbidity by age, 1995-2014. AIDS (2016) 0.76
Changes in Clinical Context for Kaposi's Sarcoma and Non-Hodgkin Lymphoma Among People With HIV Infection in the United States. J Clin Oncol (2016) 0.76
Phase I clinical trial of valacyclovir and standard of care cyclophosphamide in children with endemic Burkitt lymphoma in Malawi. Clin Lymphoma Myeloma Leuk (2012) 0.76
Spectrum of AIDS defining & non-AIDS defining malignancies in north India. Indian J Med Res (2016) 0.75
Outcomes and chemotherapy-related toxicity in HIV-infected patients with breast cancer. Clin Breast Cancer (2013) 0.75
South African Breast Cancer and HIV Outcomes Study: Methods and Baseline Assessment. J Glob Oncol (2017) 0.75
Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach. PLoS One (2017) 0.75
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med (1998) 53.26
1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep (1992) 22.29
Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med (2008) 13.72
Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med (2003) 12.23
Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet (2003) 7.94
Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med (2008) 7.71
Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS (2006) 7.08
Association of cancer with AIDS-related immunosuppression in adults. JAMA (2001) 6.80
Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer (2008) 6.13
CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis (2006) 4.67
Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol (2003) 4.15
Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study. AIDS (2009) 4.02
Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clin Infect Dis (2009) 3.91
A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr (2009) 3.76
Cohort profile: the Centers for AIDS Research Network of Integrated Clinical Systems. Int J Epidemiol (2008) 3.14
HIV infection and the risk of cancers with and without a known infectious cause. AIDS (2009) 3.13
Discordant immunologic and virologic responses to highly active antiretroviral therapy are associated with increased mortality and poor adherence to therapy. J Acquir Immune Defic Syndr (2005) 2.74
Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol (2007) 2.58
Trends in AIDS-defining and non-AIDS-defining malignancies among HIV-infected patients: 1989-2002. Clin Infect Dis (2004) 2.42
Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol (2008) 2.38
Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study. HIV Med (2003) 2.30
Spectrum of cancers among HIV-infected persons in Africa: the Uganda AIDS-Cancer Registry Match Study. Int J Cancer (2006) 2.25
The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS. Am J Epidemiol (2007) 2.19
Incidence and outcomes of malignancy in the HAART era in an urban cohort of HIV-infected individuals. AIDS (2008) 2.14
Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals. Cancer (2005) 2.09
Multiple imputation with large data sets: a case study of the Children's Mental Health Initiative. Am J Epidemiol (2009) 2.07
Survival after cancer diagnosis in persons with AIDS. J Acquir Immune Defic Syndr (2005) 1.71
Risk of cancer in people with AIDS. AIDS (1999) 1.47
Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome. AIDS (2004) 1.44
Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy. AIDS (2009) 1.42
Survival of non-Hodgkin lymphoma patients with and without HIV infection in the era of combined antiretroviral therapy. AIDS (2010) 1.22
A review of the epidemiology of cancers at the University Teaching Hospital, Lusaka, Zambia. Trop Doct (2009) 1.19
Cancer risk in persons with HIV/AIDS in India: a review and future directions for research. Infect Agent Cancer (2009) 0.83
Changes in the geographical and temporal patterns of cancer incidence among black gold miners working in South Africa, 1964-1996. Br J Cancer (2003) 0.80
Antibody neutralization and escape by HIV-1. Nature (2003) 21.48
Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med (2009) 19.90
Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA (2006) 17.93
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A (2008) 16.54
Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet (2009) 14.01
Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother (2002) 13.91
Overadjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiology (2009) 9.00
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA (2006) 7.49
Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel. Ann Intern Med (2012) 7.04
Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med (2009) 7.01
Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med (2005) 6.02
Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA (2002) 5.56
Missed visits and mortality among patients establishing initial outpatient HIV treatment. Clin Infect Dis (2009) 4.96
Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med (2005) 4.83
Competing risk regression models for epidemiologic data. Am J Epidemiol (2009) 4.75
Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J Exp Med (2005) 4.68
Impact of HIV infection and HAART on serum lipids in men. JAMA (2003) 4.01
Design and methods of the Chronic Kidney Disease in Children (CKiD) prospective cohort study. Clin J Am Soc Nephrol (2006) 3.84
The therapeutic implications of timely linkage and early retention in HIV care. AIDS Patient Care STDS (2009) 3.78
Use of multiple imputation in the epidemiologic literature. Am J Epidemiol (2008) 3.76
A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr (2009) 3.76
Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA (2004) 3.74
Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis (2010) 3.72
Distribution of health care expenditures for HIV-infected patients. Clin Infect Dis (2006) 3.72
Determinants of human immunodeficiency virus type 1 escape from the primary CD8+ cytotoxic T lymphocyte response. J Exp Med (2004) 3.48
Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol (2007) 3.46
Cohort profile: the Centers for AIDS Research Network of Integrated Clinical Systems. Int J Epidemiol (2008) 3.14
Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy. AIDS (2006) 3.11
Structural accelerated failure time models for survival analysis in studies with time-varying treatments. Pharmacoepidemiol Drug Saf (2005) 3.05
Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin Cancer Res (2010) 3.04
The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res Hum Retroviruses (2002) 2.89
Invasive cervical cancer risk among HIV-infected women: a North American multicohort collaboration prospective study. J Acquir Immune Defic Syndr (2013) 2.78
Early retention in HIV care and viral load suppression: implications for a test and treat approach to HIV prevention. J Acquir Immune Defic Syndr (2012) 2.74
Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS (2003) 2.66
Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: A meta-analysis of randomized controlled trials. Clin Infect Dis (2014) 2.65
Racial disparities in HIV virologic failure: do missed visits matter? J Acquir Immune Defic Syndr (2009) 2.58
Health care system and policy factors influencing engagement in HIV medical care: piecing together the fragments of a fractured health care delivery system. Clin Infect Dis (2011) 2.57
Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis (2012) 2.50
Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia. Cancer (2006) 2.47
Development of a quality-of-life questionnaire for adults with strabismus. Ophthalmology (2008) 2.46
Bivariate meta-analysis of sensitivity and specificity with sparse data: a generalized linear mixed model approach. J Clin Epidemiol (2006) 2.45
Trends in AIDS-defining and non-AIDS-defining malignancies among HIV-infected patients: 1989-2002. Clin Infect Dis (2004) 2.42
Failure to establish HIV care: characterizing the "no show" phenomenon. Clin Infect Dis (2007) 2.37
Clinical presentation and outcome of epidemic Kaposi sarcoma in Ugandan children. Pediatr Blood Cancer (2010) 2.37
Invited commentary: positivity in practice. Am J Epidemiol (2010) 2.33
Modeling sequence evolution in acute HIV-1 infection. J Theor Biol (2009) 2.32
Clinical outcome of HIV-infected antiretroviral-naive patients with discordant immunologic and virologic responses to highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2008) 2.29
Postnatal HIV-1 transmission after cessation of infant extended antiretroviral prophylaxis and effect of maternal highly active antiretroviral therapy. J Infect Dis (2009) 2.26
Adherence to first-line antiretroviral therapy affects non-virologic outcomes among patients on treatment for more than 12 months in Lusaka, Zambia. Int J Epidemiol (2009) 2.25
Baseline renal insufficiency and risk of death among HIV-infected adults on antiretroviral therapy in Lusaka, Zambia. AIDS (2008) 2.21
U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008. Ann Intern Med (2012) 2.18
Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy. AIDS (2008) 2.13
Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study. AIDS (2007) 2.10
Missing doses in the life span study of Japanese atomic bomb survivors. Am J Epidemiol (2013) 2.08
Treatment of cancer in sub-Saharan Africa. Lancet Oncol (2013) 2.07
Can routine clinical markers be used longitudinally to monitor antiretroviral therapy success in resource-limited settings? Clin Infect Dis (2006) 2.07
Neighborhood poverty and injection cessation in a sample of injection drug users. Am J Epidemiol (2010) 2.07
The effect of highly active antiretroviral therapy on the survival of HIV-infected children in a resource-deprived setting: a cohort study. PLoS Med (2011) 2.06
Invited Commentary: Causal diagrams and measurement bias. Am J Epidemiol (2009) 2.06
Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. Clin Infect Dis (2009) 2.05
Use of a marginal structural model to determine the effect of aspirin on cardiovascular mortality in the Physicians' Health Study. Am J Epidemiol (2002) 2.02
A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clin Cancer Res (2013) 2.02
Unrecognized chronic hepatitis C virus infection among baby boomers in the emergency department. Hepatology (2015) 1.99
Effect on mortality and virological response of delaying antiretroviral therapy initiation in children receiving tuberculosis treatment. AIDS (2010) 1.99
Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr (2002) 1.98
Association of proteinuria with race, cause of chronic kidney disease, and glomerular filtration rate in the chronic kidney disease in children study. Clin J Am Soc Nephrol (2009) 1.98
Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era. J Natl Cancer Inst (2013) 1.96
Incidence of lipoatrophy and lipohypertrophy in the women's interagency HIV study. J Acquir Immune Defic Syndr (2003) 1.95
Trends and disparities in antiretroviral therapy initiation and virologic suppression among newly treatment-eligible HIV-infected individuals in North America, 2001-2009. Clin Infect Dis (2013) 1.94
Viremia copy-years predicts mortality among treatment-naive HIV-infected patients initiating antiretroviral therapy. Clin Infect Dis (2011) 1.91
Cumulative Incidence of Cancer Among Persons With HIV in North America: A Cohort Study. Ann Intern Med (2015) 1.86
Simple adherence assessments to predict virologic failure among HIV-infected adults with discordant immunologic and clinical responses to antiretroviral therapy. AIDS Res Hum Retroviruses (2008) 1.84
Cystatin C, albuminuria, and 5-year all-cause mortality in HIV-infected persons. Am J Kidney Dis (2010) 1.84